WebDec 23, 2016 · The Biphasix™ Topical Formulation System is a platform technology for microencapsulating therapeutic compounds in multilayered, lipid-based microvesicles. … WebVANCOUVER, BC, June 4, 2024 /PRNewswire/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR) (OTCQB: PVOTF) (FSE: NPAT) is pleased to provide an update to its press release of May 25, 2024 whereby BetterLife announced that it secured "hard" lock-up agreements from shareholders of Altum Pharmaceuticals Inc. ("Altum") …
Helix BioPharma Announces Positive Interim Results From Its …
WebHelix BioPharma Corp. announced that the first ten patients that have been enrolled in its Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions have completed the pharmacokinetic primary endpoint analyses with positive findings. WebBiphasic lipid vesicles (BiphasixTM) are novel delivery systems shown to delivery low molecular weight drugs [11], *Address correspondence to this author at the College of … doctorate programs nj
Pivot Pharmaceuticals Acquires BiPhasix Transdermal Drug ... - BioSpace
WebMar 11, 2024 · Wellens Syndrome. Wellens syndrome is a pattern of inverted or biphasic T waves in V2-3 (in patients presenting with/following ischaemic sounding chest pain) that is highly specific for critical stenosis … WebWe have developed a novel transdermal lipid-based system (Biphasix) suitable for macromolecule delivery across the skin. The objective of this study was to evaluate the … WebFeb 14, 2024 · Biphasix TM is a topical formulation that is intended to be easily self-applied to human papillomavirus (HPV) -infected tissues, to deliver IFN-α into the skin and mucosal tissues. It regards with the encapsulation of the therapeutic protein in multilayered, lipid-based submicronvesicles (Altum_Pharmaceuticals_Inc.; Roohnikan et al., 2024 ). doctorate\\u0027s ij